Tryp Therapeutics Inc. is a pharmaceutical firm dedicated to discovering and advancing innovative compounds for medical conditions lacking adequate treatment options. Its primary research and development initiative, known as PFN, centers on utilizing synthetic psilocybin formulations to address a range of neuropsychiatric disorders. Key candidates within the PFN pipeline, TRP-8802 and TRP-8803, are being explored for potential applications in challenging conditions such as fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. To support its endeavors, Tryp Therapeutics has forged alliances, including an agreement with Calvert Labs for designing and conducting exploratory studies pertinent to its psilocybin-based neuropsychiatric program. Additionally, a service agreement with Fluence ensures specialized design and training for the psychotherapeutic components crucial to Tryp's clinical trial activities. Initially established as Artos Pharma Corp. in 2019, the company adopted its current name, Tryp Therapeutics Inc., in June 2020. It operates from its base in Kelowna, Canada.